


Inretio **A New Perspective** for Stroke Treatment

*Improving Mechanical Thrombectomy results in stroke care.
Minimizing the risk of clot fragmentation and downstream embolism.*



STROKE IS THE LEADING CAUSE OF DISABILITY WORLDWIDE



- **Every 40 sec.** a stroke occurs in the US.
- The total aggregate cost of stroke for US civilians is estimated at **\$103.5 billion per year**
- **85%** of strokes are ischemic

Complete revascularization (TICI=3) post Mechanical Thrombectomy (Clot Retrieving) is achieved in less than 38% of the cases

The usual outcome is the fragmentation of the clot that leads to the creation of new emboli downstream. This creates secondary damage to the brain tissue. Even a slight decrease in blood flow has a clinical impact on the procedure's outcomes and the patient's quality of life.

Current solutions are based on catheters that open inside the clot (w/o aspiration)


Current methods often lead to fragmentation of the clot. The fragments travel downstream and block smaller vessels. The surgeon needs to decide which fragment he can remove and whether the potential for disability due to the emboli is greater than the potential risk of removing it.




PREVA - PROTECTIVE CLOT RETRIEVER THAT ENCAPSULATES THE CLOT AND ALLOWS COMPLETE REVASCULARIZATION

Inretio offers the 1st and only protective clot retriever.

The device protects the brain during the procedure from sub-clots by "ensnaring" the clot and encapsulating it using our PREVA Basket



The PREVA basket encapsulates the clot from a distal position



Clot fragments are trapped in the basket, and the clot is completely removed



Patent approved in the US and CH.



Approved submission for 510K

COMPANY'S MILESTONES

- ✓ Currently in round A of funding
- ✓ Device is fully developed with a design freeze
 - ✓ Successful animal testing
 - ✓ Established US company
 - ✓ Manufacturing ability



RAVIV VINE - FOUNDER
CEO & CTO

Sr. Operation & Project Manager. Extensive experience in Engineering and Design Management, Operation Planning and development. Former design manager for a large semiconductor company. B.sc in Industrial Engineering



DR. ZIV NEEMAN (M.D)
Medical Director

Director of Diagnostic Imaging Institute, Radiology and Vascular & Interventional Nuclear Medicine, Haemek Medical Center and Assistant Professor of Radiology at the Technion Medical School, Haifa, Israel.



DR. DAVID ELMALEH
Board Chairmen & Scientific Director

Founded multiple successful medical device companies. Serves as Associate Professor, Harvard Medical School, and Director of Contrast Media Chemistry at Massachusetts General Hospital. His work has led to six approved treatments representing over billion of dollars in shareholder value. Responsible for more than 120 patents pending and issued. M.S. and Ph.D. in Organic Chemistry from Hebrew University.



DR. GAL YANIV (M.D)
Medical Advisor

Endovascular neurosurgeon at Sheba-Tel HaShomer Hospital. Published in numerous scientific publications focusing on science, radiology, and public health, including a recent publication in the New England Journal of Medicine, has presented at various scientific conferences worldwide.



A New Perspective for Stroke Treatment

Contact: raviv.vine@inretio.co.il
www.inretio.co.il